Purpose To investigate the long-term effectiveness and safety of botulinum neurotoxin A (BoNT-A) treatment in patients with blepharospasm (BEB), hemifacial spasm (HFS), and entropion (EN) and to use for the first time two modified indexes, 'botulin toxin escalation index-U' (BEI-U) and 'botulin toxin escalation index percentage' (BEI-%), in the dose-escalation evaluation. Methods All patients in this multicentre study were followed for at least 10 years and main outcomes were clinical efficacy, duration of relief, BEI-U and BEI-%, and frequency of adverse events. Results BEB, HFS, and EN patients received a mean BoNT-A dose with a significant intergroup difference (Po0.0005, respectively). The mean ( ± SD) effect duration was statistically different (P ¼ 0.009) among three patient groups. Regarding the BoNT-A escalation indexes, the mean ( ± SD) values of BEI-U and BEI-% were statistically different (P ¼ 0.035 and 0.047, respectively) among the three groups. In BEB patients, the BEI-% was significantly increased in younger compared with older patients (P ¼ 0.008). The most frequent adverse events were upper lid ptosis, diplopia, ecchymosis, and localized bruising. Conclusions This long-term multicentre study supports a high efficacy and good safety profile of BoNT-A for treatment of BEB, HFS, and EN. The BEI indexes indicate a significantly greater BoNT-A-dose escalation for BEB patients compared with HFS or EN patients and a significantly greater BEI-% in younger vs older BEB patients. These results confirm a greater efficacy in the elderly and provide a framework for long-term studies with a more flexible and reliable evaluation of drug-dose escalation.
Introduction
Benign essential blepharospasm (BEB) is a focal cranial dystonia characterized by excessive involuntary contractions of the eyelid muscles. It is usually bilateral, although it may be unilateral briefly at onset. [1] [2] [3] Initial symptoms include unpleasant sensations, eyelid fluttering, and increased blink rate in response to stimuli, progressing eventually to chronic involuntary spasms in both eyes. 4 Quality of life may be significantly impaired, with increased difficulty in reading, writing, and driving. 5 BEB is estimated to affect between 16 and 133 out of 1 000 000 individuals in the general population 6, 7 and is increasingly being recognized as cause of visual disability responsible for about 32 out of 100 000 people. 8, 9 An estimated 20 000-50 000 people are affected in the USA, with approximately 2000 new cases of BEB diagnosed annually. 7 Typically beginning in the fifth or sixth decade of life, it affects women more frequently than men (3 : 1) 10 and the elderly. 6 Botulinum neurotoxin A (BoNT-A) therapy for strabismus was introduced by Scott 11 in the early 1980s, and in 1989 the Food and Drug Administration approved BoNT-A for ophthalmologic and neurologic use in treating strabismus, blepharospasm, and hemifacial spasm (HFS). 12 Since then, BoNT-A has replaced eyelid surgery as the first-line therapy for BEB, [13] [14] [15] [16] [17] and has become the treatment of choice, as it is very successful in controlling eyelid spasms. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Although some authors have reported decreasing effectiveness with prolonged use, 23, 30 others have not observed this in the majority of patients. 24, 31 There is no evidence that prolonged treatment has any adverse effects related either to the chemodenervation of adjacent non-target muscle groups by the toxin or to the injection technique. Complications include localized bruising, ecchymosis, ptosis, exposure keratopathy, diplopia, mid-facial weakness, lagophthalmos, and dry eye.
HFS, a form of segmental myoclonus, is typically characterized by involuntary unilateral tonic and clonic contractions of the face. Onset is usually in the fifth and sixth decades and occurs more commonly in women (2 : 1) with an overall prevalence of about 10 : 100 000. However, in some populations, such as Asians, the prevalence is much higher. 32 Some patients may be genetically predisposed to developing HFS, 33 but most cases are sporadic. 9 Unlike blepharospasm, HFSs persist during sleep and are not related to hypersensory input. The anatomical basis for the spasms is believed to be mechanical irritation of the facial nerve at its exit root by compression from one or more adjacent arteries or veins. The condition may be bilateral in rare instances, and can cause significant cosmetic and functional disability. Although neurosurgical treatment is available, the potential complications and relatively high recurrence rate have made botulinum toxin A the preferred symptomatic treatment for HFS. [34] [35] [36] [37] [38] [39] As HFS rarely remits spontaneously, 40 most patients need to continue BoNT-A treatment for many years, if not for the rest of their lives. The long-term efficacy and safety of BoNT-A are, therefore, increasingly important questions. Few of the numerous published studies assessing BoNT-A treatment for HFS 34, 36, 37, 40, 41 included patients with serial treatment spanning several years and none had follow-up past 5 years.
Spastic entropion (EN) is a form of EN in which the lower eyelid margin is turned in, with a riding up of the pre-tarsal orbicularis muscle, and often accompanies involutional EN. In older patients with pre-existing lid laxity, ocular irritation after ocular surgery can sometimes cause a reflexive orbicularis muscle spasm, resulting in muscle override and EN that often resolves after a few weeks or months. Temporary relief can be achieved by weakening lower eyelid muscle tone with 5-10 U botulinum toxin injected into the pre-tarsal or pre-septal orbicularis muscle. [42] [43] [44] [45] This can completely eliminate the EN for up to 3-4 months. Botulinum toxin is a highly effective temporary EN treatment with few complications and no adverse effects on the results of surgical EN repair. 39 Treatment of blepharospasm and HFS with BoNT-A has been found to alleviate symptoms and enhance quality of life. 5, 46 Whereas most patients show long-term clinical improvement with repeated injections, however, some eventually stop responding and others fail to respond at all. 13, 24, 30 Although BoNT-A has been used for many years to treat focal dystonia-like blepharospasm, cervical dystonia, and HFS, there are little data on its long-term efficacy. 47 Furthermore, earlier studies have explored the limitations of BoNT-A; in particular, the development of secondary resistance to therapy. 48 Two recent reports suggest that higher doses and long-term use with shorter duration between treatments increase the risk of antibody formation and treatment failure. 49, 50 Recently, two studies also confirmed that higher doses of BoNT-A than recommended (50 U Â eye) may be needed for some patients. 51, 52 Therefore, it is important to determine whether efficacy with high-dose therapy can be sustained for long treatment periods without developing resistance, and whether the risk of complications is increased.
The aim of this multicentre study was to investigate the long-term effectiveness and safety of BoNT-A treatment in patients with BEB, primary HFS, and EN. We followed up regularly with patients for at least 10 years to compare the duration of relief, the number of doses needed, clinical efficacy, frequency of adverse reactions, anxiety and depressive symptoms, and antidepressant use among the three patient groups. In particular, we examined the variations in therapeutic dosage using new, modified indexes already used in other drug therapies and considered effective in the evaluation of drug-dose escalation. 53 Finally, we assessed the effectiveness of BoNT-A treatment in relationship to patient variables, such as age and gender.
Materials and methods
This multicentre study was conducted at the Ophthalmology Section, Department of Clinical Neuroscience of Palermo University, Italy and at the Service d'Ophtalmologie, Hô pital Foch, Suresnes, Paris, France. Institutional Review Board approval was obtained for this prospective study. All patients received a diagnosis of BEB, primary HFS, or EN according to published criteria and began treatment with BoNT-A (Botox, Allergan, Irvine, California, USA) injections between 1 January 1995 and 31 December 1998. Patients who were followed up for at least 10 years were enrolled in this prospective study. Both centres used standard methods for recording information, injecting BoNT-A, and assessing treatment effectiveness. 54 The injections were performed by two experienced surgeons (NG and SD) one for each centre; site of injection and the BoNT-A dosage were determined according to Helveston. 55 Patients with other neurological defects, including ocular motility or eyelid problems or facial spasm grade o2, were excluded from the study.
A total of 173 patients completed the 10-year followup: 83 patients with BEB, 65 with HFS, and 25 with EN. Of these, 18 did not attend follow-up visits for 12 months or more and were thus considered as 'dropouts.' Of the 18 dropouts, 6 had not discontinued BoNT-A therapy, but had switched to other treatment centres closer to their homes. Reasons for treatment discontinuation included death from other causes (five patients) and unsatisfactory results (four patients). Three patients dropped out for unknown reasons.
To assess the long-term effectiveness and safety of BoNT-A, we reviewed patients' medical records for the 10 years of follow-up and collected the following demographic and clinical patient data for each group: age and gender, concomitant systemic diseases, duration of disease, earlier facial paralysis, date of BoNT-A injections, total dose for each injection, number and location of injection sites, duration of effect (defined as the interval between treatment and the recurrence of symptoms severe enough to prompt patients to receive another injection), quality of the effect induced by the preceding treatment, and occurrence and duration of adverse effects. Before each injection session, patients were questioned about the results of the earlier session. The severity of diagnosis and the subjective efficacy of the BoNT-A treatment were measured using a patient self-evaluation scale. At each injection visit, changes in the patient's status were scored as no change (muscle spasms that interfered with activities of daily living or social tasks in such a way that patients continued to be socially embarrassed), moderate improvement (reduction in the frequency and duration of spasms, so that they interfered only slightly with activities of daily living or social tasks), or marked improvement (spasms in the injected muscle had ceased altogether, so that they no longer interfered with activities of daily living or social tasks). Furthermore, the self-administered questionnaire included three questions about the frequency of anxiety or depressive symptoms and use of antidepressants in the three groups of patients.
For age analysis, patients were categorized into two groups: under 65 years old and X65 years old. To assess the inter-and intra-group variations among BEB, HFS, and EN patients for scheduling dosage regimens of BoNT-A, we used two new, modified indexes already used in other fields of drug therapy and considered effective in evaluation of drug-dose escalation. 53 For the calculation of these indexes (evaluated in U and in per cent of BoNT-A-dose escalation), the botulinum toxin starting dose (BSD), the botulinum toxin maximum dose (BMD), and the total days of duration effect between treatments were recorded for each patient. The botulinum toxin escalation index in U (BEI-U) was calculated as the mean increase in botulinum toxin dosage (in U) using the following formula: (BMD-BSD)/ days. The botulinum toxin escalation index percentage (BEI-%) was calculated as the mean percentage of increase in botulinum toxin dosage from BSD using the following formula: [(BMD-BSD)/BSD]/(days Â 100). 52 Any local and systemic side effects attributable to BoNT-A therapy were evaluated at each injection time.
Statistical analysis
Statistical analysis was performed using Epi Info software, version 3.2.2 (Centers for Disease Control and Prevention, Atlanta, GA, USA) and SPSS Software (version 14.0, SPSS Inc., Chicago, IL, USA). The results are expressed as mean±standard deviation. To compare parametric variables among patient groups, univariate analysis of variance test was used and post hoc analysis with the Bonferroni test was used to determine whether there were multiple differences. When a normal distribution was not expected, the Kruskal-Wallis test was used. Changes between baseline and follow-up values were compared using the paired Wilcoxon signedrank test. Categorical variables were compared using the w 2 test and Fisher's exact test, as needed. A two-tailed P-value o0.05 was considered as statistically significant.
Results
Of the 155 patients treated with BoNT-A who completed the 10-year course of follow-up, 73 (22M/51F) patients had BEB, 58 (21M/37F) had HFS, and 24 (12M/12F) had EN (Table 1 ). There were more females (Po0.05) compared with males in both the BEB and HFS groups, but not in the EN group. There was a significant difference in mean age among the three groups, with patients in the EN group older (P ¼ 0.024) compared with the BEB and HFS patient groups (Table 1) . Furthermore, duration of the disease was significantly shorter in the EN patient group (P ¼ 0.001). No difference was found among patient groups for concomitant systemic disease, though earlier facial paralysis was more frequently found in the HFS patient group (P ¼ 0.004) ( Table 1) .
BEB, HFS, and EN patient groups received a total of 529, 391, and 64 treatments and a mean treatment number of 8.7 ( ± 7.1), 7.8 ( ± 5.5), and 2.7 ( ± 3.2), respectively, with a significant difference among diagnosis groups (P ¼ 0.006). Post hoc analysis (Bonferroni test) showed significant differences between the EN group and both BEB and HFS groups (P ¼ 0.005 and 0.020, respectively) ( Table 2 ). The frequency of patients who needed only one dose of BoNT-A were 14/73 (19.2%) for BEB, 9/58 (15.5%) for HFS, and 13/24 (54.2%) for EN, with a statistical significant difference in favour of the EN patient group (Po0.0005). On average, each patient received a mean BoNT-A dose of 28.2 (±12.2) U for BEB, 18.7 (±9.4) U for HFS, and 10.6 (±4.7) U for EN patients, with a statistically significance difference among the groups (Po0.0005). Post hoc analysis (Bonferroni test) showed significant differences between the BEB group and both HFS and EN groups (Po0.0005 in both cases) and between the HFS group and EN group (P ¼ 0.005) ( Table 2 ). The mean ( ± SD) effect duration was 18.2 (±12.3) weeks for BEB, 20.6 (±11.6) weeks for HFS, and 13.7 (±7.0) weeks for EN, with statistically significant inter-group difference (P ¼ 0.009) ( Table 2) .
For analysis of the BoNT-A escalation index, the mean ( ± SD) values of BEI-U were 0.027 ( ± 0.05), 0.008 ( ± 0.01), and 0.005 ( ± 0.01) for the BEB, HFS, and EN, respectively, groups with a statistically significant difference among the groups (P ¼ 0.035). Post hoc analysis (Bonferroni test) showed significant differences between the BEB group and both HFS and EN groups (P ¼ 0.028 and 0.022, respectively). The mean (±SD) values of BEI-% were 0.169 (±0.24), 0.053 (±0.08), and 0.068 (±0.10) for BEB, HFS, and EN groups, respectively, with a statistical significant difference among groups (P ¼ 0.047) ( Table 2 ).
Significant intra-group differences were found for mean dosages, which increased significantly (Po0.05) after the first three or four doses of treatment for both BEB and HFS patient groups. No significant difference was found in the duration effect between BEB and HFS patient groups (Figures 1 and 2) .
In 23/73 (31.5%), 18/58 (31.0%), and 1/24 (4.2%) patients with BEB, HFS, and EN, respectively, local adverse events occurred ( Table 3 ). The most frequently reported adverse reaction was upper lid ptosis, followed by diplopia, ecchymosis, and localized bruising on the side of injection. Although there was a significant difference (P ¼ 0.023) in total side effects among three Eye patient groups because of the low incidence of complications in the EN group, the incidence of side effects was similar in the BEB and HFS groups. Of the 42 patients with adverse effects, 32 had only one adverse event and two patients had more than two complications. Local adverse events were rated as mild to moderate and resolved without sequelae, but they interfered with daily activities and social tasks in approximately 30% of cases. The mean dose of BoNT-A was not significantly higher for injection sessions that induced adverse reactions than for sessions that did not (P ¼ 0.480).
Symptoms of anxiety were more frequently found in the HFS patient group (P ¼ 0.045), but there were no significant differences in depressive mood or use of antidepressants among patient groups.
According to patients' subjective impressions, nearly all treatments improved BEB and HFS, with response rates of 96 and 98%, respectively. BoNT-A was also highly effective in temporary treatment of spastic EN. No systemic side effects of BoNT-A treatment were noted, a finding consistent with the medical reports (no cases of anaphylaxis or death). There were no significant genderbased differences between the three patient groups. In patients with blepharospasm, the BEI-% was significantly increased in younger compared with older patients (P ¼ 0.008), whereas no age group differences were found in HFS patients. The intra-group analysis performed by age group and diagnosis showed that the mean dosages of BoNT-A were significantly increased during follow-up in older BEB and HFS patients (Po0.05). Furthermore, the duration effect increased significantly in these patients as treatment progressed (Po0.05). No differences in duration effect and dosage were found in younger BEB and HFS patients. No difference in the incidence of adverse effects was found according in the age group analysis for BEB (P ¼ 0.848) and HFS (P ¼ 0.166) patients.
Discussion
Our multicentre study provided a larger sample of patients with BEB, HFS, and spastic EN receiving BoNT-A treatment than would be possible with one centre alone. It also had the advantage of a 10-year follow-up. The study data support the high efficacy and good safety profile of BoNT-A for treatment of BEB, HFS, and EN T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 T13 without increased risk of side effects. A total of 96% of patients with BEB, 98% of patients with HFS, and 100% of patients with EN had significant relief of their symptoms. Although BoNT-A has been used to treat BEB, HFS, and EN for several years, most available studies describe relatively short treatment courses and follow-up, with few patients receiving continuous treatment throughout the study. 16, 25, 29, 36, 45, 56 Little work has been done to track longer-term outcomes in terms of response rates, duration of improvement, and long-term adverse reactions. 28, 40, 47, 57, 58 In our long-term, multicentre study, we have obtained at least a 96% response rate and a mean duration of improvement of 18, 21, and 14 weeks for BEB, HFS, and EN, respectively. This outcome compares well with shorter-term study results. The effectiveness of BoNT-A treatment in relieving the symptoms of BEB, HFS, and EN, as measured by the response rate and average duration of improvement, remained unchanged over the treatment years. Hence, BoNT-A use produces substantial, sustained relief over time for BEB and HFS. Our study also confirms results of other studies showing that botulinum toxin is a highly effective temporary treatment for EN, with few complications and no adverse effects on the results of surgical EN repair. 39, 45, 59 The clinical reestablishment of muscle function after BoNT-A injections requires repeated injections over long periods. 49, 50 The onset of resistance to botulinum toxin over time may be due to the immunological properties of the toxin that lead to the stimulation of antibody production, thus rendering further treatments ineffective. [48] [49] [50] [51] Greene and Fahn 49 found that patients resistant to botulinum toxin received more booster injections early after treatment, as well as higher doses compared with responsive patients. These authors, therefore, recommended that the lowest possible effective dose should be used, with treatment intervals of at least 3 months, and that booster injections be avoided. Atassi and Oshima 50 confirmed these findings by showing an association of high-dose, high-frequency botulinum toxin injections with increased antigenicity.
In our study, we have for the first time used two indexes that are already widely used in other drug therapy studies 53, 60 for assessing the medium, long-term effects of a specific treatment with uncertain duration. These indexes, namely 'botulin toxin escalation index-U' (BEI-U) and 'botulin toxin escalation index percentage' (BEI-%), include several factors, but are easy to calculate for different settings and periods and can be used to compare data in clinical trials. This dynamic tool can be useful to describe a trend in botulinum toxin treatment response, in which multiple factors can be identified in the clinical records, and can be used for the entire treatment period or for restricted periods of time.
In our prospective study, we found an increase in mean dosages for BEB and HFS patients with no statistically significant change in duration of relief during the follow-up period. Furthermore, subgroup analysis according to age (o or X65 years) indicates a significant increase in duration of relief and mean doses over the follow-up period in older but not younger BEB and HFS patients. Using BEI-U and BEI-%, we found a significantly greater BoNT-A-dose escalation for BEB patients compared with HFS or EN patients. In particular, a significantly greater BEI-% was found in younger vs older BEB patients.
These results suggest early underdosing, but only in older BEB and HFS patients. Furthermore, as reported for BoNT-A (Dysport) treatment by Truong et al, 61 the BEI-U and BEI-% data confirm a greater efficacy in the elderly, who may have lower muscle bulk than younger people and who may require a lower-dose escalation to achieve optimal benefit.
Our data provide a framework for long-term studies in which a more flexible and reliable evaluation of dose escalation as a function of variable treatment time for different diseases is required.
Consistent with earlier studies, 9,39,62 30% of our patients showed one or more side effects, including eyelid ptosis, ecchymosis, diplopia, and localized bruising occurred. Adverse events were rated as mild to moderate and resolved without sequelae. There was no evidence that prolonged treatment or age increased adverse effects. We found that anxiety was more frequent in the HFS patient group (P ¼ 0.045), emphasizing the need for treatments such as BoNT-A injections, which have showed to improve the quality of life and reduce the severity of depressive symptoms in patients with blepharospasm. 46 Some potential limitations of our study include the retrospective nature of our analysis and the use of a patient self-evaluation scale, which have earlier been used effectively, 58 rather than an observer-based rating to determine the effect of BoNT-A treatment on BEB, HFS, and EN patients. However, the large effect reported in other studies (over 90% of patients benefit) makes it difficult and probably unethical to perform controlled trials for the efficacy of BoNT-A. Future trials should explore technical factors, such as the optimal treatment intervals and the effects of different injection techniques, doses, botulinum toxin types, and formulations. Other issues include service delivery, quality of life, long-term efficacy, safety, and immunogenicity. Although botulinum neurotoxin injections are currently the mainstay of therapy, other therapies are on the horizon.
